Keywords
How to Cite
Abstract
Relevance. Axillary lymph node dissection is a redundant method of surgical treatment and axillary staging for a large number of patients receiving neoadjuvant therapy with positive lymph nodes before NCT.
Purpose of research. Improving the technique of axillary lymph node staging after neoadjuvant systemic therapy using targeted axillary dissection with I-125 microseed in addition to SLNB.
Materials and methods. The study included 212 patients with breast cancer (cT1-3N1M0) who received treatment at the breast tumors department of the N.N. Petrov NMRC of Oncology from 2019 to 2021. All patients included in the study had the cN1 initial status of the axillary lymph nodes. All patients underwent neoadjuvant systemic therapy and subsequent sentinel lymph node biopsy (SLNB). In patients with pathomorphologically proven metastatic lymph nodes (cN1) even at the initial diagnosis, lymph node marking was performed before the start of NCT and targeted axillary lymph node dissection after the completion of neoadjuvant systemic therapy. In the same patients, after SLNB and targeted axillary lymph node dissection, a complete (standard) axillary lymph node dissection was performed to determine the false-negative rate and the oncological safety of the procedure.
Results. The identification rate of only one sentinel lymph node was 21% (40 out of 193 patients), two sentinel lymph nodes - 30% (58 out of 193 patients), more than 3 - 49% (95 out of 193 patients). When only 1 sentinel lymph node was found, the false-negative rate of SLNB was 20.0% (4 of 20) (95% CI, 5.7 to 43.7). When two sentinel lymph nodes were found, the false-negative rate of SLNB was 20.0% (6 of 30) (95% CI, 7.7 to 38.6). When three sentinel lymph nodes were found, the false negative rate of SLNB was 4.7% (2 of 43) (95% CI, 0.0 to 15.8). Among 45 patients who had a microseed with the iodine-125 radioisotope installed before the start of treatment, the frequency of identifying a marked node was 100%. In 19 patients, tumor cells were found in the lymph nodes. The false-negative rate of targeted axillary dissection in combination with SLNB was 5.3% (1 of 19) (95% CI, 0.0 to 26.0).
Conclusion. Targeted axillary dissection and sentinel lymph nodes biopsy, provided that 3 SLNs are removed, are reliable methods for identifying patients in whom systemic therapy is guaranteed to achieve complete response of regional lymph nodes (ypN0), thereby relieving patients of the need to perform a crippling complete axillary lymph node dissection .
References
Kuerer HM, Sahin AA, Hunt KK et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy // Ann Surg. 1999;230:72–78.
Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer // J Clin Oncol. 2005;23:3676–3685.
Dominici LS, Negron Gonzalez VM, Buzdar AU et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2- positive breast cancer // Cancer. 2010;116:2884–2889.
Boughey JC, Suman VJ, Mittendorf EA et al. Alliance for Clinical Trials in Oncology: Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial // JAMA. 2013;310:1455–1461.
Hennessy BT, Hortobagyi GN, Rouzier R et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy // J Clin Oncol. 2005;23:9304–9311.
Lucci A, McCall LM, Beitsch PD et al. American College of Surgeons Oncology Group: Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011 // J Clin Oncol. 2007;25:3657–3663.
Kakuda JT, Stuntz M, Trivedi V et al. Objective assessment of axillary morbidity in breast cancer treatment // Am Surg. 1999;65:995–998.
Kuehn T, Bauerfeind I, Fehm T et al. Sentinellymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicentre cohort study // Lancet Oncol. 2013;14:609–618.
Boileau JF, Poirier B, Basik M et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study // J Clin Oncol. 2015;33:258–264.
Mittendorf EA, Caudle AS, Yang W et al. Implementation of the American College of Surgeons Oncology Group Z1071 trial data in clinical practice: Is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? // Ann Surg Oncol. 2014;21:2468–2473.
Boughey JC, Ballman KV, Le-Petross HT et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0–T4, N1–N2) who receive neoadjuvant chemotherapy: Results from ACOSOG Z1071 (Alliance) // Ann Surg [epub ahead of print on November 26, 2015].
Caudle A, Yang W, Mittendorf E et al. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: A prospective feasibility trial // JAMA Surg. 2015;150: 137–143.
Krishnamurthy S, Sneige N, Bedi DG et al. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma // Cancer. 2002;95:982–988.
Alternate approaches for clinical stage II or III estrogen receptor positive breast cancer neoadjuvant treatment (ALTERNATE) in post-menopausal women: A phase III study. https://www.clinicaltrials.gov/ct2/ show/NCT01953588
National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology www.nccn.org
Alvarado R, Yi M, Le-Petross H et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with nodepositive breast cancer // Ann Surg Oncol. 2012;19:3177–3184.
Classe JM, Bordes V, Campion L et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: Results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study // J Clin Oncol. 2009;27:726–732.
Newman EA, Sabel MS, Nees AV et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation // Ann Surg Oncol. 2007;14:2946–2952.
Balch GC, Mithani SK, Richards KR et al. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer // Ann Surg Oncol. 2003;10:616–621.
Mamounas EP, Brown A, Anderson S et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 // J Clin Oncol. 2005;23:2694–2702.
Donker M, Straver ME, Wesseling J et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: The MARI procedure // Ann Surg. 2015;261:378–382.
Straver ME, Loo CE, Alderliesten T et al. Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer // Br J Surg. 2010;97:1226–1231.
Choy N, Lipson J, Porter C et al. Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients // Ann Surg Oncol. 2015; 22:377–382.
Hunt KK, Yi M, Mittendorf EA et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients // Ann Surg. 2009;250: 558–566.
Семиглазов В.Ф., Семиглазов В.В., Клетцель А.Е. Неинвазивные и инвазивные опухоли молочной железы. СПБ, 2006 [Semiglazov V, Semiglazov V, Kletcel A. Neinvazivnie I invazivnie opyholi molochnoy zhelezy. SPb, 2006 (In Russ.)].
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2022